Hims & Hers Health (NYSE:HIMS) Announces Earnings Results, Misses Expectations By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) announced its earnings results on Monday. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03), FiscalAI reports. The firm had revenue of $890.37 million during the quarter, compared to analyst estimates of $893.13 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The firm’s quarterly revenue was up 48.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.06 EPS.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue grew 49% year over year to $890 million, accelerating for a second consecutive quarter; domestic revenue growth also improved to 21%. Adjusted EBITDA was $82 million, and the company generated $26 million of free cash flow.
• Subscribers fell by 100,000 sequentially to 2.8 million, which management attributed largely to deliberately lower U.S. weight-loss marketing and international brand migrations. The company expects subscriber headwinds to continue in Q4, with growth recovery anticipated after marketing ramps up in Q1.
• Hims & Hers lowered its 2026 Adjusted EBITDA guidance to $257 million–$277 million and expects Q4 revenue growth to slow to 42%–45%. Gross margin declined about seven percentage points sequentially to 57%, primarily due to a greater mix of lower-margin branded weight-loss products internationally.
• The company is expanding weight-loss options through Lilly and Novo partnerships, and raised its 2026 international revenue expectation to at least $650 million. Management says the AI-native experience reached 70% of weight-loss subscribers and users send four times as many messages, though these investments and broader international marketing may weigh on near-term results.
• Hims & Hers plans to launch Peptides+ later this month and recently expanded injectable and oral testosterone offerings, using its own pharmacy and lab infrastructure. Peptide revenue is not expected to be material in Q4, and some planned products depend on regulatory clarity.

Hims & Hers Health Stock Up 9.0%

Shares of NYSE HIMS traded up $1.73 during mid-day trading on Wednesday, hitting $20.86. The company had a trading volume of 23,622,758 shares, compared to its average volume of 14,708,043. The company has a current ratio of 0.92, a quick ratio of 0.87 and a debt-to-equity ratio of 3.85. The firm has a 50-day simple moving average of $27.95 and a two-hundred day simple moving average of $26.80. The company has a market capitalization of $4.87 billion, a PE ratio of -25.13 and a beta of 2.53. Hims & Hers Health has a one year low of $13.74 and a one year high of $40.99.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the completion of the transaction, the chief financial officer directly owned 234,527 shares of the company’s stock, valued at approximately $6,965,451.90. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the completion of the transaction, the insider owned 293,886 shares of the company’s stock, valued at approximately $8,111,253.60. This represents a 1.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 133,905 shares of company stock worth $3,826,977. Corporate insiders own 11.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HIMS shares. Needham & Company LLC reduced their price target on Hims & Hers Health from $42.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a report on Wednesday, November 4th. Citigroup lowered their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Morgan Stanley cut their price objective on shares of Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Finally, Barclays reduced their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $31.53.

Key Headlines Impacting Hims & Hers Health

Investors following HIMS have been watching these headlines:

• Positive Sentiment: Revenue rose 49% year over year to $890.4 million, and international revenue grew sharply. The growth offers a bright spot, although acquisitions contributed to expansion and profitability weakened. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, and fourth-quarter revenue guidance of $875 million–$895 million came in well below analysts’ expectations. The cut adds to concerns about the company’s earnings trajectory. Article: Hims & Hers Cuts 2026 Earnings Outlook
• Negative Sentiment: Five states have joined an FTC lawsuit alleging unlawful privacy practices, creating additional legal and reputational risk. Analysts also lowered price targets, including Morgan Stanley, which maintained an equal-weight rating while cutting its target from $28 to $25. Article: Five US States Join FTC Suit Against Hims & Hers

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.